It is made available under a CC-BY-NC-ND 4.0 International license .

#### Social and Polygenic Risk Factors for Time to Comorbid Diagnoses in Individuals 1

#### with Substance Use Disorders: A Phenome-Wide Survival Analysis 2

3	Peter B. Barr <sup>a-d</sup> , Zoe E. Neale <sup>a,b,d</sup> , Tim B. Bigdeli <sup>a,b,d,e</sup> , Chris Chatzinakos <sup>a,b</sup> ,
4	Philip D. Harvey <sup>f,g</sup> , Roseann E. Peterson <sup>a,b</sup> , and Jacquelyn L. Meyers <sup>a,b,e</sup>
5	<sup>a</sup> SUNY Downstate Health Sciences University, Department of Psychiatry and Behavioral Sciences
6	<sup>b</sup> SUNY Downstate Health Sciences University, Institute for Genomics in Health
7	° SUNY Downstate Health Sciences University, Department of Community Health Sciences
8	<sup>d</sup> VA New York Harbor Healthcare System
9	<sup>e</sup> SUNY Downstate Health Sciences University, Department of Epidemiology and Biostatistics
10	<sup>f</sup> University of Miami Miller School of Medicine
11	<sup>9</sup> Research Service, Bruce W. Carter Miami Veterans Affairs (VA) Medical Center
12	
13	Corresponding author: Peter B. Barr
14	450 Clarkson Ave, MSC 1203, Brooklyn, NY 11203

15 e-mail: peter.barr@downstate.edu.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 16 **ABSTRACT**

Importance: Persons with substance use disorders (SUD) often suffer from additional comorbidities, including psychiatric conditions and physical health problems. Researchers have explored this overlap in electronic health records (EHR) using phenome wide association studies (PheWAS) to characterize how different indicators are related to all conditions in an individual's EHR. However, analyses have been largely cross-sectional in nature.

22 **Objective:** To characterize whether various social and genetic risk factors are associated with time to 23 comorbid diagnoses in electronic health records (EHR) after the first diagnosis of SUD.

24 **Design:** Leveraging those with EHR and whole-genome sequencing data in All of Us (N = 287,012), we

25 explored whether social determinants of health are associated with lifetime risk of SUD. Next, within those

with a diagnosed SUD (N = 17,460), we examined whether polygenic scores (PGS) were associated with

27 time to comorbid diagnoses performing a phenome-wide survival analysis.

28 **Setting:** Participating health care organizations across the United States.

29 **Participants:** Participants in the All of Us Research Program with available EHR and genomic data,

Exposures: Social determinants of health and polygenic scores (PGS) for psychiatric and substance use
 disorders,

32 **Main Outcomes and Measures:** Phecodes for diagnoses derived from International Statistical 33 Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification, codes from EHR.

**Results:** Multiple social and demographic risk factors were associated with lifetime SUD diagnosis. Most strikingly, those reporting an annual income <10K had 4.5 times the odds of having an SUD diagnosis compared to those reporting 100-150K annually (OR = 4.48, 95% CI = 4.01, 5.01). PGSs for alcohol use disorders, schizophrenia, and post-traumatic stress disorder were associated with time to their respective diagnoses (HR<sub>AUD</sub> = 1.10, 95% CI = 1.06, 1.14; HR<sub>SCZ</sub> = 1.13, 95% CI = 1.06, 1.20; HR<sub>PTSD</sub> = 1.15, 95% CI = 1.08, 1.22). A PGS for ever-smoking was associated with time to subsequent smoking related comorbidities and additional SUD diagnoses HR<sub>SMOK</sub> = 1.6 to 1.16).

- 41 **Conclusions and Relevance:** Social determinants, especially those related to income have profound
- 42 associations with lifetime SUD risk. Additionally, PGS may include information related to outcomes above
- 43 and beyond lifetime risk, including timing and severity.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 44 INTRODUCTION

45 Psychiatric disorders have far-reaching consequences for affected individuals, their families, 46 communities, and the broader society<sup>1-4</sup>. Substance use disorders (SUD) in particular are extremely detrimental. An estimated 107,000 Americans died as the result of an overdose in 2021 <sup>5</sup>. In 2016, alcohol 47 48 use contributed 4.2% to the global disease burden and other drug use contributed 1.3% <sup>4</sup>. Excessive alcohol use and illicit drug use cost the United States an annual \$250 billion <sup>6</sup> and \$190 billion <sup>7</sup> 49 50 respectively. Given the substantial human and economic costs of substance use disorders, 51 understanding the ways these can contribute to risk for comorbidity has important public health 52 implications.

The proliferation of large-scale biobanks – such as The Million Veteran Program<sup>8</sup>, FinnGen<sup>9</sup>, 53 54 Biobank Japan<sup>10</sup>, UK Biobank<sup>11</sup>, and more recently, All of Us<sup>12</sup> – linking individual-level genomic data with electronic health records (EHRs) presents opportunities to further explore the relationships between 55 56 SUD, or any contributory indicators (e.g., clinical diagnoses, polygenic scores), and a wide range of outcomes. This hypothesis-free approach, referred to as a phenome-wide association study (PheWAS)<sup>10</sup>, 57 58 can aid us in better understanding patterns of comorbidity. Recent PheWAS using polygenic scores (PGS) have identified widespread associations between PGSs and a host of psychiatric and other 59 medical diagnoses<sup>11–13</sup> spanning all bodily systems (e.g., suicidal thoughts and behaviors, drug induced 60 61 psychosis, viral hepatitis, etc.) and have significant potential implications for public health strategies.

62 However, previous PheWAS have primarily used cross-sectional data among populations most 63 similar to European reference panels. In the current study, we move beyond the focus of lifetime 64 diagnosis in PheWAS to characterize whether different aspects of genetic risk, in the form of PGS, are 65 associated with time to appearance of comorbid diagnoses in the EHR after the first indication of SUD. 66 We do so by utilizing longitudinal EHR data from the All of Us Research Program, which is more 67 demographically inclusive, including Black/African-American (34%) and Hispanic or Latino/a/x (15%) 68 participants, than previous work in this area. Harnessing the longitudinal quality of the All of Us Research 69 Programs' EHR data, we explored whether: 1) social determinants of health were associated with lifetime

It is made available under a CC-BY-NC-ND 4.0 International license .

risk of SUD and 2) PGSs for psychiatric and substance use disorders were associated with the onset of comorbidities post-SUD diagnosis, by performing a phenome-wide survival analysis. Our analyses inform the degree to which genetic and environmental risk factors are important in the course of SUD related medical problems (e.g., suicidal thoughts and behaviors, drug induced psychosis, viral hepatitis, etc.).

74 The clinical utility of PGSs is an ongoing area of debate <sup>13–18</sup>. In the current analysis, we add to 75 the discussion by exploring the potential use of polygenic scores within individuals who are already 76 diagnosed. We move beyond a focus of lifetime associations in PheWAS to characterize whether different 77 elements of genetic risk, in the form of polygenic scores, are associated with onset of comorbid diagnoses 78 appearing in the EHR after the first record entry of substance use disorder (SUD). Exploring the influence 79 of polygenic scores for SUD and other co-occurring psychiatric and medical diagnoses or traits can help 80 characterize the vast pleiotropic impact of genetic risk for SUD, which could reflect shared genetic effects 81 (biological pleiotropy, e.g., a common liability contributes to risk for both SUD and PTSD, explaining the 82 comorbidity) or a causal chain of events (mediated pleiotropy, e.g., liability for AUD contributes to 83 increased alcohol use, resulting in liver disease). Knowledge gained regarding the potential medical 84 complications likely to arise in individuals with SUD with and without genetic risk for SUD can lead to 85 preventative actions or interventions that may reduce the onset of these additional comorbidities. Lastly, 86 we integrated social and genomic data in our analyses given the importance of social and clinical determinants of health in SUD<sup>19</sup>. 87

# 88 METHODS

## 89 The All of Us (AoU) Research Program

All of Us is a prospective, nationwide cohort study aiming to study the effects of environment, lifestyle, and genomics on health outcomes. Participant recruitment is predominantly done through participating health care provider organizations and in partnership with Federally Qualified Health Centers. Interested participants can enroll as direct volunteers, visiting community-based enrollment sites. Enrollment, informed consent, and baseline health surveys are administrated digitally through the

It is made available under a CC-BY-NC-ND 4.0 International license .

95 All of Us program website (https://joinallofus.org)<sup>20</sup>. Participants are then invited to undergo a basic 96 physical exam and biospecimen collection at an affiliated healthcare site. There are two types of 97 participant follow-up: passive via linkage with EHR and active by periodic follow-up surveys. We included 98 the full sample for associations between social risk factors and lifetime SUD diagnosis (N = 287,079). 99 For the genomic analyses, we included all participants who had electronic health record (EHR) and short-100 read whole genome sequence (WGS) data from release 7 (May 6, 2018 to February 23, 2023). 101 Additionally, we excluded those with self-reported military service to remove potential overlap in current 102 genome wide association studies (GWAS) such as the Million Veteran Program (MVP), leaving the final 103 sample with a lifetime SUD and genomic data at N = 12,831.

104 Genotyping

105 Approximately 245,000 individuals in the current release of AoU have available short-read 106 sequencing data. To ensure consistency across sites for DNA extraction and sequencing, AoU developed a standardized process and QC metrics across sites. Sequencing was performed on the Illumina 107 108 NovaSeq 6000 instrument. A full description of the collection, harmonization, sequencing, and population assignment pipeline has been published elsewhere<sup>21</sup>. To adjust for population structure in genetic 109 110 analyses, participants were assigned to genetic similarity clusters of those most similar to European 111 reference panels (EUR-like) and those most similar to African reference panels (AFR-like)<sup>22</sup>. Genetic 112 principal components (PCs) were generated using the *hwe\_normalized\_pca* in Hail<sup>23</sup>.

113 Electronic health records (EHRs)

We used phecodes, which are clusters of ICD-9/10-CM codes in the EHR <sup>24,25</sup>, validated previously <sup>26,27</sup>, to create lifetime diagnoses for SUD as well as the main outcomes for the PheWAS. For lifetime SUD diagnosis, we considered individuals as meeting criteria for an SUD if they had two or more outpatient or one inpatient occurrence of phecodes 316 (Substance addiction and disorders) or 317 (Alcohol-related disorders) in their EHR. Prior analyses have shown that 2 or more phecodes is a good predictor of diagnosis<sup>28,29</sup>. We focus exclusively on those with diagnoses of alcohol and drug-related It is made available under a CC-BY-NC-ND 4.0 International license .

disorders, excluding tobacco use disorders. Alcohol and other drug use disorders have the strongest evidence of a common etiology <sup>30,31</sup>, and this shared risk only overlaps minimally with risk for tobacco related disorders <sup>32</sup>. For PheWAS outcomes, we used the presence of any phecode following the initial diagnosis of SUD. We excluded phecodes for which there were fewer than 50 individuals that met criteria for a diagnosis.

# 125 Social and demographic risk factors

126 We included a variety of social and demographic measures available from the baseline AoU 127 survey. For the current analysis we included age, gender (man, woman, transgender/non-binary), race-128 ethnicity (Non-Hispanic White, Black/African-American, Hispanic or Latino/a/x, Asian American/Pacific 129 Islander, Multi-racial, and other race-ethnicity), education (less than high school, HS diploma or GED, 130 some college, college graduate, and advanced degree), household income (less than \$10k to more than 131 \$200k), marital status (never married, married, cohabitating, divorced, separated, and widowed), health insurance (have vs not), and place of birth (US born vs foreign born). We focused on the association 132 133 between social risk factors and lifetime SUD diagnosis, only. Because these items are measured at 134 baseline entry into AoU and not necessarily time of SUD diagnoses, we lack the ability to establish 135 whether potentially time-variant measures were the same before their first SUD diagnosis.

# 136 Polygenic scores (PGS)

137 We estimated PGSs, which are aggregate measures of the number of risk alleles individuals carry weighted by effect sizes from GWAS summary statistics, from multiple large-scale GWASs<sup>33–38</sup> 138 139 (Supplemental Table S1). We included these specific PGSs because: 1) there is strong genetic overlap between psychiatric and substance use disorders <sup>34–36,38–40</sup>, and 2) each of these GWAS included results 140 141 for AFR-like participants, allowing us to move beyond EUR-like only analyses. We created PGSs using PRS-CSx<sup>41</sup>, a Bayesian regression and continuous shrinkage method that estimates the posterior effect 142 143 sizes for each SNP in a given set of GWAS summary statistics. PGS accuracy decays continuously as 144 target samples differ in ancestral background from the discovery GWAS, even within relatively

It is made available under a CC-BY-NC-ND 4.0 International license .

homogenous genetic clusters <sup>42</sup>. PRS-CSx uses inputs from multiple genomic similarity clusters to
improve power of PGS in underpowered samples, typically those who are not in the EUR-like groups.
We standardized all PGSs to Z-scores.

148 We note that our paper includes language related to both race-ethnicity, which reflects socially-149 constructed categories, and genetic similarity, which uses empirical assignment based on available 150 reference panels, because both are relevant for the current analyses. First, prior work has established 151 race-ethnicity (and with it, racism and discrimination) are relevant for disparities in SUDs<sup>43-47</sup>. Second, 152 informed by best practices for current approaches to handling genetic data from diverse populations<sup>48</sup>, 153 we stratified analyses by genetic similarity and included genetic principal components, which limit the 154 possibility of false positives due to population stratification. The inclusion of both concepts is in no way 155 endorsing the notion that these reflect discrete biological categories.

156 Analytic plan

157 First, we examined the association between social, demographic, and genetic measures and 158 lifetime SUD diagnosis using logistic regression. Next, we expanded on the traditional PheWAS approach 159 by performing a phenome wide survival analysis. Rather than focusing on lifetime diagnosis, as is the 160 case in the typical PheWAS approach, we utilized Cox proportional hazards models to estimate the 161 association (in the form of hazard ratios, or HR) between time from SUD diagnosis to first documented 162 phecode diagnosis. In survival analysis, the hazard ratio (HR) is a measure used to compare the risk of 163 an event occurring at any given point in time. A HR greater than 1 indicates an increased risk of the 164 event, while a HR less than 1 suggests a reduced risk. For example, if the HR for a PGS is 1.5, it suggests 165 that they are 1.5 times more likely to experience the comorbidity earlier for every one unit increase in 166 PGS. We included the earliest diagnosis for each EHR code. In the PGS models, we stratified by genetic 167 similarity grouping (AFR-like and EUR-like) and included age at SUD diagnosis, gender, and the first 10 168 genetic principal components as covariates. We performed all survival models using the survival package 169 (version 3.7.0) in R. Finally, we meta-analyzed results via fixed-effects meta-analysis in the meta package (version 7.0.0) in R. To correct for multiple testing, we applied a false discovery rate (FDR)<sup>49</sup> of 5%. 170

It is made available under a CC-BY-NC-ND 4.0 International license .

### 171 **RESULTS**

### 172 Defining persons with lifetime SUD in EHR

Using the 2+ outpatient/1+ inpatient definition of substance use disorder diagnosis, we identified N = 17,460 individuals who met our criteria for a lifetime SUD (excluding nicotine/tobacco use disorders and those who reported active duty military service). Demographic characteristics for the full sample with available EHR data and those who met our criteria for SUD are presented in Table 1. Relative to the full sample, the SUD group was more likely to be younger, men, born in the United States, and identify as Black/African-American. This demographic breakdown of the SUD sample largely reflects the patterns seen in nationally representative samples  $^{43,44}$ .

### 180 Social and Demographic results

181 Figure 1 presents the results from the multivariable logistic regression model examining the 182 association between social and demographic risk factors and lifetime SUD diagnosis in the full phenotypic 183 sample (N = 287,079). These results largely mimicked prior analyses in earlier versions of the AoU data 184 <sup>50</sup>, whereby there was a stark gradient in lifetime SUD diagnosis across education and income, and those 185 with the lowest income (OR = 4.482; CI = 4.013, 5.006) and education (OR = 3.085; CI = 2.883, 3.302) 186 were at greatest risk for diagnosis. Additionally, women (OR = 0.618; CI = 0.598, 0.639), transgender 187 and non-binary participants (OR = 0.700; CI = 0.585, 0.838), and those born outside of the US (OR = 188 0.388; CI = 0.361, 0.418) all had lower odds of a lifetime diagnosis. Relative to non-Hispanic White 189 participants, all other racial-ethnic groups were at lower risk. Interestingly, though the base rates of 190 lifetime SUD diagnosis for Black/African-American participants were higher than others, this relationship 191 was reversed after accounting for the other social factors (OR = 0.856; CI = 0.821, 0.892). The full results 192 are available in Supplemental Table S2.

193 PGS Survival PheWAS

Moving from the full sample to those with an SUD diagnosis only, we further constrained to those of AFR-like and EUR-like genetic similarity for subsequent within-SUD survival models using PGSs (N =

It is made available under a CC-BY-NC-ND 4.0 International license .

196 12,831, see Supplemental Table S3 for stratified results). Figure 2 present the distribution of HRs for each of the PGSs, highlighting the varying magnitude of effects sizes. Associations between each PGS 197 and phecodes were enriched for reduced time to corresponding diagnoses. After adjusting for multiple 198 199 testing, only 19 of the associations remained significant (Table 2, see Supplemental Table S4 for full results). Of all the PGSs, the PGS for lifetime smoking initiation (SMOK) showed the greatest number of 200 201 trait associations, the strongest being with chronic airway obstruction (HR = 1.163; CI = 1.108, 1.220), 202 emphysema (HR = 1.140; CI = 1.061, 1.226), congestive heart failure NOS (HR = 1.140; CI = 1.070, 203 1.214), and viral hepatitis C (HR = 1.124; CI = 1.065, 1.186). Importantly, PGSs for SCZ, PTSD, and 204 AUD were associated with time to SCZ (HR = 1.126; CI = 1.060, 1.195), PTSD (HR = 1.147; CI = 1.082, 205 1.217), and AUD (HR = 1.103; CI = 1.064, 1.142), respectively.

Figure 3 presents two of the top associations between the SMOK PGS and time to subsequent chronic airway obstruction and viral hepatitis C codes. Here PGSs were stratified by standard deviations (SD), ranging from -2 SD (red) to +2 SD (purple). While the overall effect of the PGSs was small, by the end of observation, the difference in probability of "survival" between these two extremes was approximately 15% lower for chronic airway obstruction and 10% lower for viral hepatitis C in the +2 SD group.

#### 212 **DISCUSSION**

Large-scale biobanks and genetic data are becoming increasingly prevalent in health research, offering the potential to explore multiple comorbidities simultaneously. The goal of precision medicine is to realize the potential of harnessing these sources of information from to personalize treatment and stratify risk. However, much of the work to date has focused on lifetime risk for a single diagnosis. In the current analyses, we expand upon existing research by focusing on risk longitudinally and within persons who have a SUD diagnosis to begin to understand what value genetic and social risk factors might play in helping those who already have a diagnosis.

It is made available under a CC-BY-NC-ND 4.0 International license .

220 We found multiple social and demographic risk factors associated with lifetime SUD diagnosis. These results largely mimic prior findings in AoU<sup>50</sup> and in the population more broadly <sup>43,44</sup>, whereby those 221 222 who largely occupy marginalized positions are at greater risk for having a SUD. The most striking finding 223 is the gradient in income, whereby those reporting an annual household income less than \$10k annually 224 had 4.5 times the odds of having an SUD diagnosis, reflecting either social determinants as risk factors 225 or the disabling impact of SUD. Importantly the increased rate of diagnosis among those who identify as 226 Black or African-American reversed after accounting for other social determinants of health, such that 227 they were at decreased risk relative to Non-Hispanic White participants. This finding suggests the 228 increased rates of diagnoses in this population may reflect socioeconomic inequalities.

229 Focusing on genetic risk within persons who had a SUD diagnosis, polygenic scores for AUD, 230 SCZ, and SMOK demonstrated enrichment for a *longer* time to corresponding diagnoses in the EHR. 231 While this could be interpreted as some type of protective effect, the more likely explanation is those at greater risk are less likely to treatment<sup>51,52</sup>, especially as barriers to access, such as health insurance 232 233 and economic resources, were key predictors in the social demographic correlates. In terms of specific 234 PGS-phecode associations, several remained significant after correcting for multiple testing, including 235 associations between PGSs for SCZ, PTSD, and AUD and the time to their corresponding diagnoses. 236 These results increase confidence that associations are not merely spurious, as these PGSs 237 demonstrated specificity for the expected outcomes. The results also highlight the potential for assessing 238 risk in comorbid conditions among those already diagnosed with a SUD. PGS for lifetime smoking 239 initiation was associated with risk for a variety of smoking-related conditions as well as other correlates 240 of SUD (e.g. viral hepatitis C). Prior work on externalizing disorders suggests that "ever smoker" is a 241 strong proxy for externalizing risk <sup>31,53</sup>, offering a glimpse into one potential mechanism linking this PGS 242 to the comorbid diagnoses.

This work has several important limitations. First, we lacked the social and demographic risk factors measured at time of diagnosis and could not establish the time ordering between these measures. As the AoU database grows through recruitment, data generation, and passive data collection via

It is made available under a CC-BY-NC-ND 4.0 International license .

246 constantly updating EHRs, we will be able to explore the prospective association between important 247 social determinants of health and diagnoses. Second, the use of EHR data, while convenient, is also 248 confounded by access and healthcare utilization. We cannot discern whether associations are truly 249 reflective of the progression in disease process or whether they reflect propensity for help seeking when 250 available in a healthcare setting. Lastly, though we have attempted to be more inclusive in the genetic 251 analyses, we still lacked sufficient GWAS summary statistics for other genetic similarity groups to include 252 here. As a field, we must continue to strive to ensure results from genetic discoveries can be applied to 253 all populations, equitably<sup>48</sup>.

254 Harnessing the longitudinal data in the All of Us database, we have demonstrated the importance 255 of various social conditions for the lifetime diagnosis of substance use disorders. Annual income is 256 especially relevant in disparities of SUD. Additionally, we have also shown that in persons who have a 257 SUD diagnosis, various measures of genetic risk were associated with time to subsequent diagnoses in 258 their EHR, moving beyond typical cross-sectional approaches. While there is considerable work to be 259 done for the use of social, clinical, and biological data within a healthcare setting, the current results 260 demonstrate the potential of these approaches. Future work should endeavor to integrate across levels 261 of analysis in a longitudinal framework.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 262 **REFERENCES**

- Ferrari A. Global, regional, and national burden of 12 mental disorders in 204 countries and
   territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry*. 2022;9(2):137-150. doi:10.1016/S2215-0366(21)00395-3
- Murray CJL, Mokdad AH, Ballestros K, et al. The state of US health, 1990-2016: Burden of
   diseases, injuries, and risk factors among US states. *JAMA Journal of the American Medical Association*. 2018;319(14):1444-1472. doi:10.1001/jama.2018.0158
- 269 3. Reitsma MB, Fullman N, Ng M, et al. Smoking prevalence and attributable disease burden in 195
- 270 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease
- Study 2015. The Lancet. 2017;389(10082):1885-1906. doi:https://doi.org/10.1016/S01406736(17)30819-X
- Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and
   drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden
- of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987-1012. doi:10.1016/S22150366(18)30337-7
- U.S. Overdose Deaths In 2021 Increased Half as Much as in 2020 But Are Still Up 15%. Accessed
   May 15, 2022. https://www.cdc.gov/nchs/pressroom/nchs\_press\_releases/2022/202205.htm
- 279 6. Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, Brewer RD. 2010 National and State Costs of
- 280 Excessive Alcohol Consumption. Am J Prev Med. 2015;49(5):e73-e79.
   281 doi:10.1016/j.amepre.2015.05.031
- 282 7. National Drug Intelligence Center. *National Drug Threat Assessment*. Vol 2019. United States
   283 Department of Justice; 2011.
- B. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to study
   genetic influences on health and disease. J Clin Epidemiol. 2016;70:214-223.
   doi:10.1016/j.jclinepi.2015.09.016

- 287 9. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped
  288 isolated population. *Nature*. 2023;613(7944):508-518. doi:10.1038/s41586-022-05473-8
- Nagai A, Hirata M, Kamatani Y, et al. Overview of the BioBank Japan Project: Study design and
   profile. *J Epidemiol.* 2017;27(3):S2-S8. doi:10.1016/j.je.2016.12.005
- 11. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and
   genomic data. *Nature*. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z
- The All of Us Research Program Investigators. The "All of Us" Research Program. *New England Journal of Medicine*. 2019;381(7):668-676. doi:10.1056/nejmsr1809937
- Lewis CM, Vassos E. Polygenic risk scores: From research tools to clinical instruments. *Genome Med.* 2020;12(1):1-11. doi:10.1186/s13073-020-00742-5
- Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic
  risk scores may exacerbate health disparities. *Nat Genet.* 2019;51(4):584-591.
  doi:10.1038/s41588-019-0379-x
- Wray NR, Lin T, Austin J, et al. From Basic Science to Clinical Application of Polygenic Risk
   Scores: A Primer. *JAMA Psychiatry*. 2021;78(1):101-109. doi:10.1001/jamapsychiatry.2020.3049
- Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores.
   *Nat Rev Genet*. 2018;19(9):581-590. doi:10.1038/s41576-018-0018-x
- Murray GK, Lin T, Austin J, McGrath JJ, Hickie IB, Wray NR. Could Polygenic Risk Scores Be
  Useful in Psychiatry?: A Review. *JAMA Psychiatry*. 2021;78(2):210-219.
  doi:10.1001/jamapsychiatry.2020.3042
- 307 18. Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. *Nat Rev* 308 *Cardiol.* 2022;19(5):291-301. doi:10.1038/s41569-021-00638-w
- 309 19. Barr PB, Driver MN, Kuo SIC, et al. Clinical, environmental, and genetic risk factors for substance
  310 use disorders: characterizing combined effects across multiple cohorts. *Mol Psychiatry*.
  311 2022;27(11):4633-4641. doi:10.1038/s41380-022-01801-6

- 312 20. National Institutes of Health. "All of Us" Research Program. U.S Department of Health and Human
   313 Service- National Institute of Health. 2021. https://allofus.nih.gov/
- Bick AG, Metcalf GA, Mayo KR, et al. Genomic data in the All of Us Research Program. *Nature*.
   2024;627(8003):340-346. doi:10.1038/s41586-023-06957-x
- 316 22. National Academies of Sciences and Medicine E. Using Population Descriptors in Genetics and
- 317 Genomics Research: A New Framework for an Evolving Field. The National Academies Press;
- 318 2023. doi:10.17226/26902
- 319 23. Hail Team. Hail 0.2. Accessed December 10, 2024. https://github.com/hail-is/hail
- 320 24. Denny JC, Bastarache L, Ritchie MD, et al. Systematic comparison of phenome-wide association
- 321 study of electronic medical record data and genome-wide association study data. *Nat Biotechnol*.
- 322 2013;31(12):1102-1110. doi:10.1038/nbt.2749
- Wu P, Gifford A, Meng X, et al. Mapping ICD-10 and ICD-10-CM codes to phecodes: Workflow
   development and initial evaluation. *J Med Internet Res*. 2019;21(11):1-13. doi:10.2196/14325
- 325 26. Wei WQ, Teixeira PL, Mo H, Cronin RM, Warner JL, Denny JC. Combining billing codes, clinical
- 326 notes, and medications from electronic health records provides superior phenotyping performance.
- 327 Journal of the American Medical Informatics Association. 2016;23(e1):20-27. 328 doi:10.1093/jamia/ocv130
- Wei WQ, Bastarache LA, Carroll RJ, et al. Evaluating phecodes, clinical classification software,
   and ICD-9-CM codes for phenome-wide association studies in the electronic health record. *PLoS One*, 2017;12(7):e0175508.
- Zheutlin AB, Dennis J, Linnér RK, et al. Penetrance and pleiotropy of polygenic risk scores for
   schizophrenia in 106,160 patients across four health care systems. *American Journal of Psychiatry*. 2019;176(10):846-855. doi:10.1176/appi.ajp.2019.18091085
- Bigdeli TB, Voloudakis G, Barr PB, et al. Penetrance and Pleiotropy of Polygenic Risk Scores for
   Schizophrenia, Bipolar Disorder, and Depression among Adults in the US Veterans Affairs Health
- 337 Care System. *JAMA Psychiatry*. 2022;79(11):1092-1101. doi:10.1001/jamapsychiatry.2022.2742

- 338 30. Barr PB, Dick DM. The Genetics of Externalizing Problems. *Curr Top Behav Neurosci*. 2020;47:93339 112. doi:10.1007/7854\_2019\_120
- 340 31. Karlsson Linnér R, Mallard TT, Barr PB, et al. Multivariate analysis of 1.5 million people identifies 341 genetic associations with traits related to self-regulation and addiction. *Nat Neurosci*. Published
- 342 online 2021:1-10. doi:10.1038/s41593-021-00908-3
- 343 32. Kendler KS, Myers J. The boundaries of the internalizing and externalizing genetic spectra in men
  344 and women. *Psychol Med.* 2014;44(3):647-655. doi:10.1017/S0033291713000585
- 345 33. Saunders GRB, Wang X, Chen F, et al. Genetic diversity fuels gene discovery for tobacco and 346 alcohol use. *Nature 2022 612:7941*. 2022;612(7941):720-724. doi:10.1038/s41586-022-05477-4
- 347 34. Levey DF, Stein MB, Wendt FR, et al. Bi-ancestral depression GWAS in the Million Veteran
  348 Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat*349 *Neurosci.* Published online May 27, 2021. doi:10.1038/s41593-021-00860-2
- 350 35. Levey DF, Galimberti M, Deak JD, et al. Multi-ancestry genome-wide association study of cannabis
   use disorder yields insight into disease biology and public health implications. *Nat Genet.* 2023;55(12):2094-2103. doi:10.1038/s41588-023-01563-z
- 353 36. Nievergelt CM, Maihofer AX, Atkinson EG, et al. Genome-wide association analyses identify 95
  354 risk loci and provide insights into the neurobiology of post-traumatic stress disorder. *Nat Genet.*355 2024;56(5):792-808. doi:10.1038/s41588-024-01707-9
- 37. Kranzler HR, Zhou H, Kember RL, et al. Genome-wide association study of alcohol consumption
  and use disorder in 274,424 individuals from multiple populations. *Nat Commun.* 2019;10(1):1499.
  doi:10.1038/s41467-019-09480-8
- 359 38. Zhou H, Kember RL, Deak JD, et al. Multi-ancestry study of the genetics of problematic alcohol
  360 use in over 1 million individuals. *Nat Med.* 2023;29(12):3184-3192. doi:10.1038/s41591-023361 02653-5
- 362 39. Deak JD, Zhou H, Galimberti M, et al. Genome-wide association study in individuals of European
   363 and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent

- 364 genome-wide significant risk loci. *Mol Psychiatry*. 2022;27(10):3970-3979. doi:10.1038/s41380 365 022-01709-1
- 366 40. Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic
  367 biology in schizophrenia. *Nature*. 2022;604(7906):502-508. doi:10.1038/s41586-022-04434-5
- 368 41. Ruan Y, Lin YF, Feng YCA, et al. Improving polygenic prediction in ancestrally diverse populations.
- 369 Nat Genet. 2022;54(5):573-580. doi:10.1038/s41588-022-01054-7
- 370 42. Ding Y, Hou K, Xu Z, et al. Polygenic scoring accuracy varies across the genetic ancestry
  371 continuum. *Nature*. 2023;618(7966):774-781. doi:10.1038/s41586-023-06079-4
- 43. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder results from
- 373 the national epidemiologic survey on alcohol and related conditions III. *JAMA Psychiatry*.
  374 2015;72(8):757-766. doi:10.1001/jamapsychiatry.2015.0584
- Grant BF, Saha TD, June Ruan W, et al. Epidemiology of DSM-5 drug use disorder results from
  the national epidemiologic survey on alcohol and related conditions-III. *JAMA Psychiatry*.
  2016;73(1):39-47. doi:10.1001/jamapsychiatry.2015.2132
- Williams DR. Race, Socioeconomic Status, and Health The Added Effects of Racism and
  Discrimination. *Ann N Y Acad Sci.* 1999;896(1):173-188. doi:https://doi.org/10.1111/j.17496632.1999.tb08114.x
- Williams DR, Collins C. Racial residential segregation: a fundamental cause of racial disparities in
   health. *Public Health Rep.* 2001;116(5):404-416. http://www.ncbi.nlm.nih.gov/pubmed/12042604
- Williams DR, Mohammed SA. Discrimination and racial disparities in health: evidence and needed
   research. *J Behav Med*. 2009;32(1):20-47. doi:10.1007/s10865-008-9185-0
- 48. Peterson RE, Kuchenbaecker K, Walters RK, et al. Genome-wide Association Studies in
   Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell*.
- 387 2019;179(3):589-603. doi:10.1016/j.cell.2019.08.051

It is made available under a CC-BY-NC-ND 4.0 International license .

- 388 49. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
  389 Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*.
  390 1995;57(1):289-300. http://www.jstor.org/stable/2346101
- 391 50. Barr PB, Bigdeli TB, Meyers JL. Prevalence, Comorbidity, and Sociodemographic Correlates of
   392 Psychiatric Diagnoses Reported in the All of Us Research Program. *JAMA Psychiatry*.
   393 2022;79(6):622-628. doi:10.1001/jamapsychiatry.2022.0685
- Mojtabai R, Evans-Lacko S, Schomerus G, Thornicroft G. Attitudes Toward Mental Health Help
   Seeking as Predictors of Future Help-Seeking Behavior and Use of Mental Health Treatments.

396 Psychiatric Services. 2016;67(6):650-657. doi:10.1176/appi.ps.201500164

- Blanco C, Iza M, Rodríguez-Fernández JM, Baca-García E, Wang S, Olfson M. Probability and
   predictors of treatment-seeking for substance use disorders in the U.S. *Drug Alcohol Depend*.
   2015;149:136-144. doi:https://doi.org/10.1016/j.drugalcdep.2015.01.031
- 400 53. Deak JD, Clark DA, Liu M, et al. Alcohol and nicotine polygenic scores are associated with the
  401 development of alcohol and nicotine use problems from adolescence to young adulthood.
  402 Addiction. 2022;117(4):1117-1127. doi:10.1111/add.15697

403

404

It is made available under a CC-BY-NC-ND 4.0 International license .

# 405 **ACKNOWLEDGEMENTS**

This study was supported in part by National Institute of Mental Health (R01MH125938: Drs Peterson, Bigdeli, Chatzinakos, and Meyers); the National Institute of Drug Abuse (R01DA050721: Dr Barr; R01DA060596: Drs Meyers, Barr, Chatzinakos, and Neale), and the National Institute on Alcohol Abuse and Alcoholism (R01AA030010: Drs Meyers, Barr, Chatzinakos, and Neale). Computing costs associated with this work was supported by R01MH125938 (PI: Peterson). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

413

414 The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: 415 Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 416 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 417 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and 418 Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 419 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and 420 Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 421 OD025315: 1 OT2 OD025337: 1 OT2 OD025276. In addition, the All of Us Research Program would not 422 be possible without the partnership of its participants.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 423 FIGURE CAPTIONS

- 424 Figure 1: Association results for social risk factors and lifetime SUD diagnosis.
- Adjusted odds ratios (OR) and corresponding 95% confidence intervals presented on the x-axis.
  Reference categories indicated by (ref). Models included each of the above measures, simultaneously.
  NH = Non-Hispanic, AAPI = Asian American or Pacific Islander, HS = high school, GED = general
  educational development.
- 429
- 430 Figure 2: Distribution of hazard ratios for PGSs from multivariable survival PheWAS.
- Violin and box-and-whisker plots for conditional hazard ratios (HR) between each PGS and phecodes in
  the meta-analyzed results. All models included each PGS, simultaneously. Thick black line in the center
  of each box represents the median value. The edges of the box represent the 25<sup>th</sup> and 75<sup>th</sup> percentile.
  AUD = alcohol use disorder, CUD = cannabis use disorder, DEP = depression, PTSD = post-traumatic
  stress disorder, SMOK = ever smoker, SCZ = schizophrenia.
- 436
- 437 Figure 3: Survival plots for chronic airway obstruction and viral hepatis C across SMOK PGS levels.
- Predicted survival curves for chronic airway obstruction and viral hepatis C as a function of SMOK PGS
  levels (red = -2 SD, yellow = -1 SD, green = mean, blue = +1 SD, purple = +2 SD). All models adjusted
  for age at diagnosis, gender, genetic similarity, and first 10 genetic principal components (PCS).

It is made available under a CC-BY-NC-ND 4.0 International license .

	Full sample (N = 287, 012)		SUD (N = 17,460)			
	<u>N/Mean</u>	<u>%/SD</u>	N/Mean	<u>%/SD</u>	<u>X</u> <sup>2</sup>	
Age (mean)	55.10	0.02	51.40	0.29	*	
Woman	171,431	59.73	8,310	47.59	*	
Man	108,209	37.70	8,585	49.17	*	
Transgender/Non-Binary	1,893	0.66	142	0.81		
Gav/Lesbian/Bisexual	24,706	8.61	2.259	12.94	*	
Straight/Heterosexual	252,386	87.94	14,406	82.51	*	
Asian	0 0 2 0	2 80	01	0.46	*	
Asian Black/African Amorican	0,030 57 177	2.00	5 992	22.60	*	
Hispanic or Latino/a/y	17 699	19.92	2,668	15 28	*	
	1 605	0.56	2,000	0.20	*	
Non-Hispanic White	150 402	52 40	7 216	0.29 /1 33	*	
Native Hawaijan/Pacific Islander	297	0.10	23	0.13	*	
Multiple race-ethnicities	10 771	3 75	668	3.83	*	
Other race-ethnicity not listed	3,017	1.05	261	1.49	*	
Born outside the US	43,635	15.20	1,095	6.27	*	
US-born	238,162	82.98	15,969	91.46	*	
Less than high school	27 867	9 71	3 417	19 57	*	
High school diploma or GED	56 778	19 78	5 822	33.34	*	
Some college	72,938	25.41	4,771	27.33	*	
College graduate	62,550	21.79	1.664	9.53	*	
Advanced degree	57,696	20.10	922	5.28	*	
Asian Black/African American Hispanic or Latino/a/x MENA Non-Hispanic White Native Hawaiian/Pacific Islander Multiple race-ethnicities Other race-ethnicities Other race-ethnicity not listed Born outside the US US-born Less than high school High school diploma or GED Some college College graduate Advanced degree	8,038 57,177 47,699 1,605 150,402 297 10,771 3,017 43,635 238,162 27,867 56,778 72,938 62,550 57,696	2.80 19.92 16.62 0.56 52.40 0.10 3.75 1.05 15.20 82.98 9.71 19.78 25.41 21.79 20.10	81 5,883 2,668 50 7,216 23 668 261 1,095 15,969 3,417 5,822 4,771 1,664 922	0.46 33.69 15.28 0.29 41.33 0.13 3.83 1.49 6.27 91.46 19.57 33.34 27.33 9.53 5.28	* * * * * * * * * * * * *	

441 p < .05, MENA = Middle East and Nort Africa

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2: Phenome wide Significant Associations from Survival Models									
PGS	Phecode description	HR	95% CI (lower)	<u>95% CI (upper)</u>					
SMOK	Chronic airway obstruction	1.163	1.108	1.220					
PTSD	Posttraumatic stress disorder	1.147	1.082	1.217					
SMOK	Emphysema	1.140	1.061	1.226					
SMOK	Congestive heart failure (CHF) NOS	1.140	1.070	1.214					
SMOK	Obstructive chronic bronchitis	1.129	1.060	1.204					
SCZ	Schizophrenia	1.126	1.060	1.195					
SMOK	Viral hepatitis C	1.124	1.065	1.186					
SMOK	Tobacco use disorder	1.116	1.086	1.148					
AUD	Alcohol-related disorders	1.103	1.064	1.142					
SMOK	Substance addiction and disorders	1.055	1.030	1.081					
AUD	GERD	0.937	0.910	0.966					
AUD	Sepsis	0.909	0.862	0.959					
AUD	Inflammatory and toxic neuropathy	0.899	0.856	0.945					
SMOK	Hypothyroidism NOS	0.897	0.846	0.951					
SCZ	Migraine	0.896	0.852	0.942					
AUD	Herpes zoster	0.795	0.717	0.881					
AUD	Glucocorticoid deficiency	0.790	0.693	0.899					
AUD	Neutropenia	0.747	0.639	0.872					
CUD	Cystic mastopathy	0.689	0.576	0.825					

442

HR = hazard ratio; PGS = polygenic score; SMOK = ever smoker; PTSD = post-traumatic stress disorder;

443 SCZ = schizophrenia; AUD alcohol use disorder; CUD = cannabis use disorder; NOS =. Not otherwise specified; GERD = Gastroesophageal reflux disease. Full results available in Supplementary Table S4.

444





# Chronic Airway Obstruction



# Viral Hepatitis C

